(Q37852662)

24 August 2017

1 reference

title

EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities (English)

1 reference

24 August 2017

1 reference

Gilda da Cunha Santos

1

object named as

Gilda da Cunha Santos

0 references

author name string

Mauro Ajaj Saieg

2

1 reference

24 August 2017

William Geddie

3

1 reference

24 August 2017

Natasha Leighl

4

1 reference

24 August 2017

publication date

11 March 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

119

1 reference

24 August 2017

issue

2

1 reference

24 August 2017

page(s)

80-91

1 reference

Personalized medicine and inhibition of EGFR signaling in lung cancer

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Oncogenic growth factor receptors: implications for signal transduction therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

EGFR antagonists in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Comparison between epidermal growth factor receptor (EGFR) gene expression in primary non-small cell lung cancer (NSCLC) and in fine-needle aspirates from distant metastatic sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Is cytology reliable for epidermal growth factor receptor gene evaluation in non-small cell lung cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Assessment of mean EGFR gene copy number is a highly reproducible method for evaluating FISH in histological and cytological cancer specimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Chromogenic in situ hybridization to detect EGFR gene copy number in cell blocks from fine-needle aspirates of non small cell lung carcinomas and lung metastases from colo-rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Evaluation of 7q31 region improves the accuracy of EGFR FISH assay in non small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

EGFR mutations and lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

An alternative approach to determining therapeutic choices in advanced non-small cell lung carcinoma (NSCLC): maximizing the diagnostic procedure and the use of low-volume lung biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound- and endobronchial ultrasound-guided fine needle cytological aspirates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Successful treatment of lung cancer with gefitinib and EGFR mutation status determination using EBUS-TBNA samples in an extremely old patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Targeted use of fluorescence in situ hybridization (FISH) in cytospin preparations: results of 298 fine needle aspirates of B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Molecular techniques in cytopathology practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Translational studies for target-based drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

EUS-FNA and biomarkers for the staging of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Micrometastasis, molecular markers, and their future role with EUS-guided FNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Detection of EGFR and KRAS mutations in fine-needle aspirates stored on Whatman FTA cards: is this the tool for biobanking cytological samples in the molecular era?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Cells carry the clue for targeted treatment: a new horizon for cytopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

7 January 2021

EGFR expression as an ancillary tool for diagnosing lung cancer in cytology specimens

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

7 January 2021

Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

7 January 2021

Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

7 January 2021

Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

7 January 2021

Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

7 January 2021

Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

7 January 2021

Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

7 January 2021

Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

7 January 2021

Transbronchial fine-needle aspiration, epidermal growth factor receptor mutations, and the scorpion's touch

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

7 January 2021

Neoplastic pulmonary cytology: why all the fuss over "NSCLC"?

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20150

7 January 2021

Identifiers

DOI

10.1002/CNCY.20150

1 reference

24 August 2017

1 reference